Article Text

This article has a correction. Please see:

PDF
Successful use of rituximab in a patient with Churg–Strauss syndrome and refractory central nervous system involvement
  1. Jasemine Saech1,
  2. Kasia Owczarzyk1,
  3. Sylvia Rösgen2,
  4. Hela Petereit3,
  5. Michael Hallek1,
  6. Andrea Rubbert-Roth1
  1. 1University Hospital of Cologne, Department of Internal Medicine I, Cologne, Germany
  2. 2University Hospital of Cologne, Department of Radiology, Cologne, Germany
  3. 3Holy-Ghost Hospital of Cologne, Cologne, Germany
  1. Correspondence to Dr Jasemine Saech, University Hospital of Cologne, Department of Internal Medicine I, Kerpenerstrasse 62, 50924 Cologne, Germany; jasemine.saech{at}uk-koeln.de

Statistics from Altmetric.com

The major clinical manifestations of Churg–Strauss syndrome (CSS) include asthma, hypereosinophilia and the extrapulmonary manifestation of systemic vasculitis.1 The involvement of the central nervous system (CNS) is less common (<10%), with significant morbidity and mortality in affected patients.2 Glucocorticoids combined with cyclophosphamide represent the treatment of choice in patients with severe involvement of the heart, nervous system or kidney.3 In the case of intolerance to cyclophosphamide, plasma exchange, interferon and mycophenolate mofetil (MMF) have been suggested as alternatives.4 A few case reports on the use of rituximab in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and CSS are available5,,7; however, none reported on patients with …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.